Oxytocin- and aluminium fluoride-induced phospholipase C activity and prostaglandin F2 alpha secretion during the ovine luteolytic period.
A series of studies was conducted to characterize changes in components of the cell signalling cascade that mediates oxytocin-induced prostaglandin F2 alpha (PGF2 alpha) synthesis at the onset of luteolysis in sheep. In the first experiment, caruncular tissue was dissected from 20 ewes on days 12-15 of the oestrous cycle, and incubated for the measurement of phospholipase C (PLC) activity or secretion of PGF2 alpha. Activation of GTP-binding proteins with aluminium fluoride stimulated both inositol phosphate accumulation and PGF2 alpha secretion on all days examined. However, oxytocin did not stimulate PLC activity or PGF2 alpha accumulation until day 13. While the ability of oxytocin to stimulate PLC activity increased after day 13, oxytocin-induced PGF2 alpha secretion declined slightly from day 13 to 15, suggesting that cell signalling components downstream from PLC modulate the response to oxytocin after day 13. Oxytocin failed to stimulate PGF2 alpha synthesis on day 14 after oestrus. Secretion of endogenous luteal oxytocin may have rendered uterine tissues collected on day 14 refractory to oxytocin in vitro. Therefore, a second study was conducted in ovariectomized, steroid replaced ewes. Ovarian steroids were administered to mimic endogenous changes in progesterone and oestradiol. The temporal patterns of PGF2 alpha synthesis in response to oxytocin and pharmacological agents were similar to uterine tissues from cyclic ewes in the first experiment; however, the magnitude of the response was less. These data suggest that oxytocin receptors are absent or are not coupled to PLC until day 13 after oestrus.
Graf
G A
GA
Department of Animal Sciences, University of Kentucky, Lexington 40546-0215, USA.
Burns
P D
PD
Silvia
W J
WJ
D017607:Aluminum Compounds / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D046508:Culture Techniques; D015237:Dinoprost / Q000378:metabolism*; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D005459:Fluorides / Q000494:pharmacology*; D019204:GTP-Binding Proteins / Q000378:metabolism; D007295:Inositol Phosphates / Q000378:metabolism; D003341:Luteolysis; D010052:Ovariectomy; D010121:Oxytocin / Q000494:pharmacology*; D011374:Progesterone / Q000097:blood / Q000494:pharmacology; D012756:Sheep / Q000378:metabolism*; D015398:Signal Transduction; D013268:Stimulation, Chemical; D013997:Time Factors; D010738:Type C Phospholipases / Q000378:metabolism*
D017607:Aluminum Compounds; D007295:Inositol Phosphates; D011374:Progesterone; D004958:Estradiol; D010121:Oxytocin; D015237:Dinoprost; D010738:Type C Phospholipases; D019204:GTP-Binding Proteins; D005459:Fluorides; C032311:aluminum fluoride